ePRO: A Maturing and Widely-Preferred Market
Industry Standard Research
The adoption of technologies is generally increasing throughout clinical trials. It took the industry some time to fully adopt and integrate EDC as the de facto standard for data collection but that has happened. ISR's data show EDC is now the data collection method of choice for the vast majority of clinical trials. We're also witnessing the maturation of other technologies in clinical trials such as online dashboards that aggregate clinical trial metrics and report on study progress; we see clinical sites relying more heavily on their electronic medical records for feasibility and patient recruitment; and we find clinical investigators and study coordinators prefer electronic patient reported outcomes (ePRO) over paper PRO.
The stage is set for further proliferation of not only ePRO, but a much broader set of eClinical service offerings and value propositions. Service providers, technology developers, and CROs need to know where their products stand and sponsors should be aware of how their partners are viewed by one of the most important cogs in the clinical development wheel: the investigative sites.
—Industry Standard Research, www.ISRreports.com/.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
